Trump's Marijuana Order Is Stuck at the DEA. Here's What That Means for Canopy Growth.

President Trump's Executive Order to reschedule marijuana to Schedule III has stalled at the DEA due to bureaucratic delays and a temporary stay issued in September. While Canopy Growth shares initially surged on the news, they have since declined significantly. However, the article argues that U.S. rescheduling is a secondary concern for the Canada-based company, which faces more pressing operational challenges including persistent losses and dilutive equity financing.

10/18/2026, 2:15 PM • The Motley Fool

Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?

The article compares two major cannabis companies navigating industry challenges. Canopy Growth focuses on premium Canadian cannabis and European medical sales but faces internal control weaknesses and significant losses. Tilray Brands has diversified into beverages and international markets, posting record Q1 revenue of $257M with improving margins. The author recommends Tilray as the better choice due to its larger scale, diversified revenue streams, and clearer path to profitability, though both stocks remain risky investments in a volatile industry.

10/15/2026, 5:54 PM • The Motley Fool

3 Huge Red Flags From Tilray's Q1 Earnings Report

Tilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.

10/12/2026, 2:25 PM • The Motley Fool

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?

Canopy Growth and Tilray Brands represent diverging strategies in the cannabis industry. Canopy pursues a lean, brand-focused model with emphasis on U.S. expansion, while Tilray has diversified into craft beverages and wellness products. Both companies reported significant net losses in FY 2026 despite revenue growth, with Tilray showing better financial metrics (higher revenue, lower debt-to-equity ratio, higher gross margin) but greater business complexity. The article suggests Tilray may appeal to diversification-focused investors, while Canopy attracts those betting on pure cannabis growth, though both carry substantial risks.

10/10/2026, 5:18 PM • The Motley Fool

Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?

Canopy Growth is approaching positive adjusted EBITDA with Q1 fiscal 2027 revenue up 13% year-over-year to $57.4 million, narrowing adjusted EBITDA losses to $2.3 million from $5.7 million. The MTL Cannabis acquisition is driving growth across Canadian medical, adult-use, and international markets, with expected $7.2 million in annual cost savings. However, free cash flow deteriorated to a $18.5 million outflow, raising concerns about cash generation despite an encouraging balance sheet with $241.4 million in cash.

09/30/2026, 11:23 AM • The Motley Fool

Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock

Tilray Brands has lost over 50% of its value in 2026 and is down 95% over five years, making it a highly risky investment. However, the bullish case centers on potential U.S. marijuana legalization, which could trigger significant stock appreciation even before full legalization occurs. The company has diversified into beverages and alcohol to position itself for future U.S. market entry. While the stock could surge on legalization discussions similar to Canada's 2018 experience, investors should be aware of substantial risks and uncertainty.

09/15/2026, 10:39 AM • The Motley Fool

Canopy Growth's Revenue Grew 13% Last Quarter. Investors Barely Reacted. Here's Why.

Canopy Growth reported 13% year-over-year revenue growth to $58.9 million in Q1 fiscal 2027, with improved gross margins and narrowed EBITDA losses. However, the stock barely moved because the company remains unprofitable, continues burning cash ($18.6M free cash outflow), and some growth came from acquisitions rather than organic expansion. Investors are skeptical after years of failed turnaround promises and want proof of sustainable profitability before rewarding the stock.

09/07/2026, 7:20 AM • The Motley Fool

Should You Buy Canopy Growth Stock on the Rebound?

Canopy Growth showed strong Q1 fiscal 2027 results with 13% revenue growth across all business divisions, improved gross margins, and significantly reduced losses. However, the company remains a penny stock with over 400% share dilution in three years. While the business turnaround is promising, the article recommends most investors monitor rather than buy, citing the sector's history of underperformance and the need to see sustained improvement before investing.

09/05/2026, 7:15 AM • The Motley Fool

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

The cannabis sector is undergoing consolidation as weaker players exit and stronger companies acquire competitors. Curaleaf has made an unsolicited $4 per share bid for Aurora Cannabis. The article identifies Canopy Growth and Tilray Brands as the biggest potential winners in this consolidation trend, with Canopy benefiting from its balance sheet reset and Tilray diversifying beyond marijuana into alcohol and consumer brands.

08/21/2026, 8:15 AM • The Motley Fool

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?

Curaleaf launched an unsolicited $272 million bid to acquire Aurora Cannabis at $4 per share, signaling renewed consolidation in the cannabis industry. The move raises questions about whether Canopy Growth could become the next acquisition target. While Canopy has valuable global medical cannabis assets and established brands, its complex corporate structure and ongoing turnaround make it a less obvious fit for potential acquirers.

08/16/2026, 12:30 AM • The Motley Fool

Thinking About Buying Canopy Growth? You May Want to Wait for This 1 Thing to Happen First.

The key catalyst for Canopy Growth stock is the DEA's decision on rescheduling cannabis to Schedule III, which could happen soon given President Trump's executive order. While rescheduling would benefit the company by allowing consolidation of its U.S. affiliate and eliminating section 280E tax deductions, the article advises waiting rather than buying ahead of the announcement, as past regulatory news has caused temporary surges followed by selloffs. Long-term investors should view cannabis stocks as a legalization bet, not a short-term binary trade.

07/25/2026, 10:30 AM • The Motley Fool

President Trump's Major Marijuana Move: What It Means for Canopy Growth, Green Thumb, and Tilray

President Trump's executive order to reschedule medical marijuana from Schedule I to Schedule III provides limited benefits to major cannabis companies. While the rescheduling eliminates IRS Section 280E tax restrictions for medical marijuana businesses, it only applies to medical products, not the larger recreational market. Canopy Growth, Tilray, and Green Thumb Industries face minimal direct impact due to their business structures and market focus, though the change creates new regulatory compliance burdens.

07/17/2026, 5:30 AM • The Motley Fool

Canopy Growth's Medical Marijuana Sales Are Soaring. Is the Beaten-Down Stock Ready to Rebound?

Canopy Growth reported strong 27% growth in its medical marijuana division in Q4 fiscal 2026, but the rest of the business showed weakness. The recreational marijuana segment grew only 1% in Q4, international cannabis sales fell 7% year-over-year, and the Storz & Bickel vaporizer business declined 14%. The company continues to report negative earnings and faces declining gross margins, making it a risky investment despite one strong division.

06/28/2026, 9:15 AM • The Motley Fool

Trulieve Makes History As First US Cannabis Stock On NYSE

Trulieve Cannabis Corp. became the first U.S. cannabis company to list on a major U.S. stock exchange (NYSE: TRLV), enabled by the Trump administration's reclassification of cannabis to Schedule III. The company separated its medical and adult-use operations to meet exchange requirements. Competitors like Curaleaf and Verano are preparing for similar uplistings, while Canadian producers remain on Nasdaq. The listing has energized the cannabis sector.

06/10/2026, 5:25 PM • Benzinga

The Market Overreacted to the DEA's Marijuana Rescheduling -- Here's What It Means for Canopy Growth Stock Now

The DEA's rescheduling of marijuana from Schedule I to Schedule III in April 2026 was initially seen as historic but has had muted impact. The rescheduling only applies to medical marijuana and provides limited benefits like IRS Section 280E relief. Canopy Growth, a major Canadian cannabis company, cannot fully capitalize on these changes due to its non-controlling interest in its U.S. affiliate Canopy USA, whose results remain unconsolidated. The analyst concludes the rescheduling won't materially affect Canopy Growth soon and does not recommend the stock as a buy.

06/02/2026, 1:15 AM • The Motley Fool